Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Commercial Capsules: Pfizer's Tax Reform M&A Pause; PARP Deals; PD-1 Sales; Antimicrobial Financing

Executive Summary

Pfizer's CEO says uncertainty over US tax reform was staying his hand in M&A; following AstraZeneca's MYSTIC miss, Bristol-Myers Squibb and Merck & Co. were duly grilled over their own PD-1/CTLA-4 combination programs; recent deals highlight gathering enthusiasm for combining PARP and PD-1/PD-L1 inhibition. Commercial Capsules rounds up key commercial news reported recently by sister publication Scrip.

Advertisement

Related Content

Amplyx Raises $67m For Antifungals Against Life-Threatening Pathogens
Finance Watch: Canaan Closes New VC Fund; CARB-X Backs More Antibiotics
Exclusive Remicade Contracts Are Slowing Biosimilar Uptake
The PARP Combo Race Is On: Clovis And Bristol Partner On Rubraca
Merck's Keytruda Claims Market Leadership In First-line Lung Cancer
Post-MYSTIC, Bristol Renews CTLA-4 Vows, But Is "Not Wedded" In Lung Cancer
A Whopper Of A Deal: AZ Hands Half Of Lynparza To Merck
MYSTIC Misses: Devastation For AstraZeneca As Imfinzi Fails PFS Endpoint In NSCLC
Tesaro's Zejula Expansion Includes Keytruda Combo, Lung Cancer

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

PS121253

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel